Financial results
Financial
Growth
Our 2023-2024 financial results are in line with our 2025 trajectory and our ambitions for 2030.
The sustained growth in sales volume reflects our drive to make our medicines available to an ever-increasing number of patients throughout the world. Furthermore, the considerable expansion in oncology sales and the progress in therapeutic innovation over 2023-2024 confirm the Group’s focus in this area. The majority of the targets the Group had set for 2025 will be reached or even exceeded, such as the €1 billion target for oncology revenue, or €1.3 billion in EBITDA. Today, the Group is on track to achieve its 2030 ambitions. In addition, our independence we enjoy, underpinned by being governed by a non-profit foundation, enables us to finance growth as we are free to reinvest our profits to develop our business.
Group revenue and performance
10.8%
In 2023-2024, the Servier Group’s consolidated revenue rose 10.8% on the previous year to reach €5,902 million. This underlines the Group’s growth trajectory and its ability to provide a constantly expanding range of medicines to patients.
Our performance was driven in particular by the considerable year-on-year growth in sales volumes of our brand-name and generic medicines throughout the world.
These figures were boosted by a solid performance in oncology in the United States and of Daflon®, which remains the Group’s best-selling medicine. Over the past four years, Group revenue has risen on average by 9.9%.
Group revenue (€bn) and EBITDA (€bn and % of Group revenue)
9.9%
Over the past four years, the Group’s turnover has grown by an average of 9.9%.
In 2023-2024, EBITDA1 totaled €1.313 billion, representing a ratio to revenue of 22.2%, compared with 19.2% in 2022-2023. These figures were boosted by the significant rise in medicine sales over the year, especially in oncology, combined with solid cost control throughout the Group. The Group has thereby exceeded its 2024-2025 target of reaching EBITDA of 21.7% and remains confident in its ability to achieve its ambition of 30% by 2030.
Renowned expertise in cardiometabolism and venous diseases, as well as an effective oncology strategy
Sales of medicines in cardiometabolism and venous diseases account for 49% of consolidated revenue in 2023-2024, compared with 53% in 2022-2023. The 3.7% growth in sales was driven by the performance of Daflon®, which remains the Group’s best-selling medicine.
In accordance with the Group’s strategy, oncology accounts for an increasing share of consolidated revenue, now representing 24% and generating €1.430 billion in 2023-2024, compared with 20% in 2022-2023. This performance was bolstered by sales increasing 33.0% on the previous year.
Breakdown of Group revenue by geographic region (€m and annual average growth)
International footprint
The proportion of revenue generated within the European Union represented 43% of consolidated growth, rising 10.2% year on year. The US subsidiary remains the Group’s leading entity in terms of sales of brand-name medicines, bringing in €879 million, up 38.4% on the €635 million recorded in 2022-2023. This market accounts for 15% of Group revenue, and growth in this area validates the Group’s strategy in the United States and oncology in particular.
Breakdown of Group revenue
1 EBITDA is used as an operational performance indicator that is defined as current operating income minus decreases such as asset sales and other non-recurring costs (EBITDA: Earnings before interest, taxes, depreciation, and amortization).